Immune cell functions are regulated by co-inhibitory and co-stimulatory receptors. The first
two generations of cancer immunotherapy agents consist primarily of antagonist antibodies …

The advent of immunotherapy has had a major impact on the outcome and overall survival
in many types of cancer. Current immunotherapeutic strategies typically aim to (re) activate …

The adoptive transfer of T cells that have been genetically modified to express a CD19-
specific chimeric antigen receptor (CAR) is effective for treating human B cell malignancies …

Immunotherapy using mAbs, such as rituximab, is an established means of treating
hematological malignancies. Abs can elicit a number of mechanisms to delete target cells …

Herein, we describe the generation of potent NK cell engagers (NKCEs) based on single
domain antibodies (sdAbs) specific for NKp46 harboring the humanized Fab version of …

Tumor cell‐surface markers are usually overexpressed or mutated protein receptors for
which spatiotemporal regulation differs between and within cancers. Single‐molecule …

Epidermal growth factor receptor (EGFR)-targeted cancer therapy such as anti-EGFR
monoclonal antibodies and tyrosine kinase inhibitors have demonstrated clinical efficacy …

Nowadays, personalized cancer therapy relies on small molecules, monoclonal antibodies,
or antibody–drug conjugates (ADC). Many nanoparticle (NP)-based drug delivery systems …

Targeted agents have improved the efficacy of chemotherapy for cancer patients, however,
there remains a lack of understanding of how these therapies affect the unsuspecting …

The ability to deliver proteins and peptides across the plasma membrane into the cytosol of
living mammalian cells would be highly impactful for both basic science and medicine …